The British Business Bank has committed £1.1bn to the UK's life sciences sector, aiming to attract further investment from pension funds and support the growth of domestic firms. The state lender's chief investment officer, Leandros Kalisperas, stated the bank has had to "throw the kitchen sink at the problem" of financing life sciences.
Of the total backing, £832m has been distributed across 20 life science funds, with an additional £302m invested in numerous domestic scale-ups. Recent investments include £25m in Alchemab Therapeutics and £15m in Cambridge university spinout T-Therapeutics.
The bank is also working to entice institutional investors, including signatories of the Mansion House accord, to allocate more pension capital to private assets and venture capital firms, including those in life sciences. The accord saw 11 major UK pension money managers pledge to invest five per cent of their assets in private markets and unlisted equities by 2030.
While the bank's focus is on domestic growth, it has also committed €58m (£48.3m) to Sofinnova Crossover Fund II, a Parisian-based fund that supports firms across Europe. Kalisperas noted that attracting deep pools of capital for specialist firms cannot rely solely on UK-only funds, acknowledging the role of European specialists in the sector.
Separately, the National Wealth Fund recently invested £147m of debt financing into One North Quay in Canary Wharf, a development expected to become one of Europe's largest commercial science buildings. This project, set for completion in 2028, also received capital pledges from Barclays and Emirates NBD, bringing the total to £368.5m.